Our COVID Vaccine Statement and other related resources for patients and our researchers and research staff are available on the COVID-19 Updates webpage.
Mohan Suntharalingam MD
Closed to Accrual
To evaluate if the addition of cetuximab to paclitaxel, cisplatin, and radiation improves overall survival compared to paclitaxel, cisplatin, and radiation alone in patients with esophageal cancer who are treated without surgery
Histologic proof of primary squamous cell or adenocarcinoma of the esophagus or gastroesophageal junction Involvement of the GE junction with Siewert type I or II tumors Stage T1N1M0; T2-4, Any N, M0; Any T, Any N, M1a
We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More
NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.